$0.42
-0.48%Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Quality against peers; 50 is the peer median.
No reported financials for this company yet: it has too few SEC filings to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
Fundamentals: trailing twelve months to Jun 2026, from the latest 10-K and 10-Qs.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.